ARA-290 (Cibinetide): A Non-Erythropoietic EPO-Derived Tissue-Protective Peptide

Research summary. ARA-290, also known as cibinetide, is an 11-amino-acid peptide derived from the aqueous-exposed face of helix B of erythropoietin (EPO). It was engineered to retain the cytoprotective and anti-inflammatory properties of EPO while losing its haematopoietic (red-blood-cell-stimulating) activity. The peptide acts at the innate repair receptor (IRR), a heteromeric receptor composed of the EPO receptor and CD131 (the common β receptor), which is upregulated on injured and inflamed tissues.

Molecular profile

• Sequence: pyro-Glu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (pE-EQLERALNSS)
• Molecular formula: C₅₁H₈₄N₁₆O₂₁
• Molecular weight: ~1257.3 g/mol
• PubChem CID: 91810664
• CAS Number: 1208243-50-8
• Synonyms: cibinetide, pyroglutamate helix B surface peptide (pHBSP)

The N-terminal pyroglutamate residue improves resistance to aminopeptidases and contributes to the peptide's plasma stability profile, although the in-vivo half-life remains short (minutes), which has shaped how the compound is studied.

Mechanism of action

The work of Brines, Cerami, and colleagues established that EPO has two functional faces: a high-affinity site that binds the homodimeric EPOR responsible for erythropoiesis, and a lower-affinity site (helix B surface) that engages the heteromeric IRR (EPOR / CD131) responsible for tissue protection. ARA-290 was designed to interact selectively with the latter [1].

Engagement of the IRR triggers downstream cytoprotective and anti-inflammatory cascades — including JAK2-STAT signalling, PI3K/Akt activation, and inhibition of NF-κB-driven pro-inflammatory cytokine production — without activating the haematopoietic EPOR homodimer. The IRR is constitutively expressed at low levels but is markedly upregulated in tissues exposed to ischaemic, mechanical, or inflammatory injury, which provides a degree of tissue and condition selectivity that whole EPO lacks.

Preclinical research highlights

Anti-inflammatory and tissue-protective effects. In rodent models of ischaemia-reperfusion injury (cardiac, renal, cerebral), administration of ARA-290 has been reported to reduce infarct size, suppress local cytokine production (TNF-α, IL-6, IL-12), and decrease apoptosis of parenchymal cells [1].

Islet-cell transplant models. Mouse studies of pancreatic islet transplantation have demonstrated that ARA-290 prolongs graft survival and improves functional outcomes, an effect attributed primarily to suppression of macrophage activation and inflammatory cytokine release in the peri-graft environment.

Endothelial repair and angiogenesis. Preclinical work on endothelial colony-forming cells (ECFCs) has shown that ARA-290 supports their survival, proliferation, migration, and homing to ischaemic tissue. These observations have positioned the peptide as a candidate for studying vascular repair after ischaemic insult.

Neuropathic pain models. A significant body of preclinical and translational work has examined ARA-290 in models of small-fibre neuropathy. The proposed mechanism combines IRR-mediated suppression of neuroinflammation with reported modulation of TRPV1 channel activity in nociceptive afferents.

Autoimmune models. In murine models of systemic lupus erythematosus, ARA-290 administration has been associated with reduced anti-dsDNA autoantibody titres and attenuated kidney pathology, consistent with the peptide's broader anti-inflammatory profile.

Translational research

ARA-290 is one of the relatively rare research peptides that has progressed into formal clinical investigation. Phase 2 studies, primarily conducted in patients with diabetic neuropathy and sarcoid neuropathy, reported reductions in pain scores and increases in corneal nerve fibre density. In 2016, Araim Pharmaceuticals received U.S. FDA orphan drug designation for cibinetide for the treatment of painful sarcoid neuropathy. The compound has not received marketing authorisation, and its development has progressed slowly, with the public scientific literature remaining the primary record of its activity.

Current research status

ARA-290 remains an investigational peptide under academic and small-company development. It serves several research roles:

• Probe compound for studying the innate repair receptor and the haematopoietic-versus-tissue-protective duality of EPO signalling
• Tool for investigating non-EPOR-driven cytoprotection in ischaemic and inflammatory injury models
• Candidate molecule for studying neuropathic pain mechanisms, particularly small-fibre neuropathy

The molecule's tissue-selectivity (driven by injury-induced IRR upregulation) and its absence of erythropoietic activity make it a useful research tool for dissecting which downstream effects of EPO are tied to which receptor complex.

Key takeaways for researchers

• ARA-290 is an 11-amino-acid peptide derived from helix B of EPO.
• It engages the innate repair receptor (EPOR/CD131 heterodimer) and avoids the homodimeric EPOR responsible for erythropoiesis.
• It has been studied across cardiac, renal, vascular, neuropathic pain, and autoimmune preclinical models.
• It has progressed through Phase 2 clinical investigation and holds U.S. FDA orphan-drug designation, but is not approved as a therapeutic.

References

1. Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences USA. 2008;105(31):10925–10930.
2. Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular Medicine. 2014;20:658–666.

---

This article is provided for educational and research purposes only. ARA-290 (cibinetide) is an investigational peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.